London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 82.07B |
| Revenue (ttm) | 8.59B |
| Net Income (ttm) | -765.40M |
| Shares Out | n/a |
| EPS (ttm) | -2.97 |
| PE Ratio | n/a |
| Forward PE | 22.32 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 224 |
| Average Volume | 1,092 |
| Open | 429.50 |
| Previous Close | 427.08 |
| Day's Range | 428.56 - 433.69 |
| 52-Week Range | 290.87 - 492.61 |
| Beta | 0.51 |
| RSI | 27.31 |
| Earnings Date | May 5, 2025 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
These large-cap stocks were the worst performers in the last week. Are they in your portfolio? argenx SE (NASDAQ: ARGX) shares tumbled 15.40% after the company reported first-quarter results . Vertex...
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft
The Investment Committee give you their top names to watch for the second half.
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft
The Investment Committee give you their top names to watch for the second half.
Vertex Pharma extends selloff as Wolfe downgrades after Q1 miss
Vertex Pharmaceuticals (VRTX) stock faces a downgrade at Wolfe Research based on the company's recent lower than expected Q1 2025 results. Read more here.
SA analyst upgrades: TSLA, MSFT, AMD, PLTR, VRTX, ONON, CB
Explore recent stock upgrades by Seeking Alpha: TSLA, MSFT, AMD & more! Discover insights and investment strategies for outperforming the market.
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip
Vertex On Track To Significantly Improve Revenue And Earnings By 2030
Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain manage...
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
Vertex posted Q1 EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U.S. ... Full story available on Benzinga.com
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
On Monday, Vertex Pharmaceuticals Incorporated VRTX reported lower-than-expected first-quarter 2025 earnings.
Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Heres Why.
Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More
U.S. equities were lower at midday as the market watched for any possible deals involving Trump administration tariffs and awaited tomorrow's statement from the Federal Reserve policymakers following ...
Vertex Pharmaceuticals Stock Sinks as Costs Soar
Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped.
Tech faces turbulence as energy stocks surge: A detailed market analysis
Sector Overview The tech sector is navigating choppy waters today, with major players showing mixed results. Microsoft (MSFT) slipped slightly at -0.34%, while Nvidia (NVDA), a significant semiconduct...
Why Vertex Pharmaceuticals Stock Is Sinking Today
Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks
Vertex stock skidded Tuesday on a series of first-quarter setbacks that included light sales, slow uptake for two drugs and a paused study.
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Needham c...
Stocks making the biggest moves premarket: Palantir Technologies, Ford Motor, Vertex Pharmaceuticals, DoorDash and more
These are some of the stocks posting the largest moves in premarket trading.
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday. Shares of Ichor Holdings, Ltd . (NASDAQ: ICHR) fell sharply in today's pre-market trading after th...
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday.
This Vertex Pharmaceuticals Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Vertex: Improved Outlook Despite First Quarter Miss (Rating Upgrade)
Vertex Pharmaceuticals missed Q1 revenue and EPS estimates but this is not a cause for concern as the full-year outlook has improved. Alyftrek is off to a good start and early launch metrics of Journa...
Vertex Pharmaceuticals Incorporated 2025 Q1 - Results - Earnings Call Presentation
Vertex Pharmaceuticals Incorporated (VRTX) Q1 2025 Earnings Call Transcript
Vertex misses on both lines in Q1 as 2025 revenue forecast narrowed
Vertex Pharmaceuticals Q1 results missed estimates, but the company raised its 2025 revenue outlook.
Vertex Pharmaceuticals Stock Falls On Q1 Earnings, Revenue Miss — Company Raises Low End Of FY25 Revenue Guidance
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) reported first-quarter financial results after the market close on Monday. Here’s a look at the key highlights from the period . Q1 Revenue: $2.77 billion ve...